Literature DB >> 17923549

C-reactive protein level and risk of aging macula disorder: The Rotterdam Study.

Sharmila S Boekhoorn1, Johannes R Vingerling, Jacqueline C M Witteman, Albert Hofman, Paulus T V M de Jong.   

Abstract

OBJECTIVE: To examine whether C-reactive protein (CRP) level is a risk factor for aging macula disorder (AMD) in a general population.
METHODS: We examined serum high-sensitivity CRP (HsCRP) levels in 4914 participants of the population-based Rotterdam Study at risk for AMD. After a mean follow-up of 7.7 years, 561 cases of early and 97 cases of late incident AMD (iAMD) were identified. We used Cox proportional hazards regression models to estimate hazard ratios and corresponding 95% confidence intervals (CIs).
RESULTS: After adjustment for age and sex, hazard ratios were 1.11 (95% CI, 1.02-1.21) per standard deviation increase in HsCRP level for early iAMD and 1.28 (95% CI, 1.02-1.60) for late iAMD. Hazard ratios for early iAMD increased per quartile increase in HsCRP level as follows: second quartile, 1.19 (95% CI, 0.94-1.52); third quartile, 1.29 (95% CI, 1.01-1.64); and fourth quartile, 1.33 (95% CI, 1.05-1.70). The risk of late iAMD was higher in all upper quartiles of HsCRP.
CONCLUSION: Elevated baseline levels of HsCRP were associated with the development of early and late AMD in this large population-based cohort.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17923549     DOI: 10.1001/archopht.125.10.1396

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  37 in total

Review 1.  Complement pathway biomarkers and age-related macular degeneration.

Authors:  M Gemenetzi; A J Lotery
Journal:  Eye (Lond)       Date:  2015-10-23       Impact factor: 3.775

Review 2.  Immunopathological aspects of age-related macular degeneration.

Authors:  Mrinali Patel; Chi-Chao Chan
Journal:  Semin Immunopathol       Date:  2008-02-26       Impact factor: 9.623

3.  Intravitreal injection of (99)Tc-MDP inhibits the development of laser-induced choroidal neovascularization in rhesus monkeys.

Authors:  Kunbei Lai; Chenjin Jin; Shu Tu; Yunfan Xiong; Rui Huang; Jian Ge
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-01-05       Impact factor: 3.117

4.  The prevalence and analysis of risk factors for age-related macular degeneration: 18-year follow-up data from the Speedwell eye study, United Kingdom.

Authors:  L-Y Ngai; N Stocks; J M Sparrow; R Patel; A Rumley; G Lowe; G Davey Smith; Y Ben-Shlomo
Journal:  Eye (Lond)       Date:  2011-03-25       Impact factor: 3.775

Review 5.  Genetics of age-related macular degeneration: current concepts, future directions.

Authors:  Margaret M Deangelis; Alexandra C Silveira; Elizabeth A Carr; Ivana K Kim
Journal:  Semin Ophthalmol       Date:  2011-05       Impact factor: 1.975

6.  C-reactive protein and complement factor H polymorphism interaction in advanced exudative age-related macular degeneration.

Authors:  Roham Soheilian; Mohammad Hossein Jabbarpour Bonyadi; Hamidreza Moein; Mojgan Babanejad; Alireza Ramezani; Mehdi Yaseri; Masoud Soheilian
Journal:  Int Ophthalmol       Date:  2016-10-24       Impact factor: 2.031

7.  Effects of antioxidant components of AREDS vitamins and zinc ions on endothelial cell activation: implications for macular degeneration.

Authors:  Shemin Zeng; Jasmine Hernández; Robert F Mullins
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-27       Impact factor: 4.799

8.  The Association of Statin Use with Age-Related Macular Degeneration Progression: The Age-Related Eye Disease Study 2 Report Number 9.

Authors:  Shaza N Al-Holou; William R Tucker; Elvira Agrón; Traci E Clemons; Catherine Cukras; Frederick L Ferris; Emily Y Chew
Journal:  Ophthalmology       Date:  2015-10-04       Impact factor: 12.079

9.  Plasma levels of amyloid beta and other proinflammatory mediators in patients with age-related macular degeneration.

Authors:  Robyn Guymer; Tania Cipriani; Kay D Rittenhouse; Lyndell Lim; Liubov D Robman; Wenlin Li; Wenlian Wang; Shibing Deng; Poulabi Banerjee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-03-07       Impact factor: 3.117

10.  The Rotterdam Study: 2010 objectives and design update.

Authors:  Albert Hofman; Monique M B Breteler; Cornelia M van Duijn; Harry L A Janssen; Gabriel P Krestin; Ernst J Kuipers; Bruno H Ch Stricker; Henning Tiemeier; André G Uitterlinden; Johannes R Vingerling; Jacqueline C M Witteman
Journal:  Eur J Epidemiol       Date:  2009       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.